Scienture Holdings, Inc. (NASDAQ:SCNX) Sees Large Increase in Short Interest

by · The Cerbat Gem

Scienture Holdings, Inc. (NASDAQ:SCNX – Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 2,650,027 shares, a growth of 22.7% from the November 30th total of 2,160,531 shares. Approximately 8.3% of the company’s shares are short sold. Based on an average daily volume of 2,174,444 shares, the short-interest ratio is presently 1.2 days. Based on an average daily volume of 2,174,444 shares, the short-interest ratio is presently 1.2 days. Approximately 8.3% of the company’s shares are short sold.

Analysts Set New Price Targets

SCNX has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research report on Monday. Wall Street Zen lowered Scienture from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Get Our Latest Stock Report on Scienture

Scienture Stock Performance

SCNX traded up $0.01 during trading on Wednesday, hitting $0.51. 517,750 shares of the stock were exchanged, compared to its average volume of 6,423,035. The firm has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $1.05. The firm has a market cap of $20.72 million, a price-to-earnings ratio of -0.51 and a beta of 2.95. Scienture has a 1 year low of $0.46 and a 1 year high of $6.45.

Scienture (NASDAQ:SCNX – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million for the quarter. Scienture had a negative return on equity of 25.18% and a negative net margin of 10,364.22%.

Scienture Company Profile

(Get Free Report)

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

See Also